Paper39698264
Advances in Development of Drug Treatment for Hemophilia with Inhibitors.
Wichaiyo S. ACS Pharmacol Transl Sci, 2024. Cited by 5 papers, by iCite.
Cite this record
ConductScience Library. Advances in Development of Drug Treatment for Hemophilia with Inhibitors. Papers, record 39698264. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39698264
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References65
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 34077951 | A factor VIIIa-mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice. | Blood | 2021 | https://conductscience.org/library/papers/34077951 | PubMed |
| 2 | 30151972 | Phase 1, single-dose escalating study of marzeptacog alfa (activated), a recombinant factor VIIa variant, in patients with severe hemophilia. | J Thromb Haemost | 2018 | https://conductscience.org/library/papers/30151972 | PubMed |
| 3 | 38142846 | FRONTIER1: a partially randomized phase 2 study assessing the safety, pharmacokinetics, and pharmacodynamics of Mim8, a factor VIIIa mimetic. | J Thromb Haemost | 2024 | https://conductscience.org/library/papers/38142846 | PubMed |
| 4 | 12781551 | Haemophilias A and B. | Lancet | 2003 | https://conductscience.org/library/papers/12781551 | PubMed |
| 5 | 30174468 | An investigational RNAi therapeutic targeting antithrombin for the treatment of hemophilia A and B. | J Blood Med | 2018 | https://conductscience.org/library/papers/30174468 | PubMed |
| 6 | 27913543 | Hemophilia and inhibitors: current treatment options and potential new therapeutic approaches. | Hematology Am Soc Hematol Educ Program | 2016 | https://conductscience.org/library/papers/27913543 | PubMed |
| 7 | 25428222 | Toward optimal therapy for inhibitors in hemophilia. | Blood | 2014 | https://conductscience.org/library/papers/25428222 | PubMed |
| 8 | 28691557 | Emicizumab Prophylaxis in Hemophilia A with Inhibitors. | N Engl J Med | 2017 | https://conductscience.org/library/papers/28691557 | PubMed |
| 9 | 35999026 | A phase 1b/2 clinical study of marstacimab, targeting human tissue factor pathway inhibitor, in haemophilia. | Br J Haematol | 2023 | https://conductscience.org/library/papers/35999026 | PubMed |
| 10 | 30264916 | The future of bypassing agents for hemophilia with inhibitors in the era of novel agents. | J Thromb Haemost | 2018 | https://conductscience.org/library/papers/30264916 | PubMed |
| 11 | 15328151 | The use of recombinant factor VIIa in the treatment of bleeding disorders. | Blood | 2004 | https://conductscience.org/library/papers/15328151 | PubMed |
| 12 | 26897598 | The past and future of haemophilia: diagnosis, treatments, and its complications. | Lancet | 2016 | https://conductscience.org/library/papers/26897598 | PubMed |
| 13 | 37646676 | Phase 3 Trial of Concizumab in Hemophilia with Inhibitors. | N Engl J Med | 2023 | https://conductscience.org/library/papers/37646676 | PubMed |
| 14 | 17951326 | The haemostatic role of tissue factor pathway inhibitor. | Arterioscler Thromb Vasc Biol | 2008 | https://conductscience.org/library/papers/17951326 | PubMed |
| 15 | 31859415 | Laboratory coagulation tests and emicizumab treatment A United Kingdom Haemophilia Centre Doctors' Organisation guideline. | Haemophilia | 2020 | https://conductscience.org/library/papers/31859415 | PubMed |
| 16 | 38523289 | Haemophilia care in Asia: Learning from clinical practice in some Asian countries. | Haemophilia | 2024 | https://conductscience.org/library/papers/38523289 | PubMed |
| 17 | 32744769 | WFH Guidelines for the Management of Hemophilia, 3rd edition. | Haemophilia | 2020 | https://conductscience.org/library/papers/32744769 | PubMed |
| 18 | 37916312 | Emicizumab: the hemophilia A game-changer. | Haematologica | 2024 | https://conductscience.org/library/papers/37916312 | PubMed |
| 19 | 37341887 | Concizumab: First Approval. | Drugs | 2023 | https://conductscience.org/library/papers/37341887 | PubMed |
| 20 | 28670147 | Many factor VIII products available in the treatment of hemophilia A: an embarrassment of riches? | J Blood Med | 2017 | https://conductscience.org/library/papers/28670147 | PubMed |
Cited by3
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 5 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42078236 | Clinical Scenarios in Hospitalized Patients With Hemophilia. | Cureus | 2026 | https://conductscience.org/library/papers/42078236 | PubMed |
| 41892982 | Structural Enablers of Rare Disease Treatment Coverage in Latin America and the Caribbean: Lessons from Emicizumab. | J Mark Access Health Policy | 2026 | https://conductscience.org/library/papers/41892982 | PubMed |
| 41473775 | Rebalancing Hemostasis: Fitusiran as a First-in-Class RNAi Therapy in Hemophilia A and B. | Health Sci Rep | 2026 | https://conductscience.org/library/papers/41473775 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| SERPINC1 | 462 | PubTator's text mining | https://conductscience.org/library/genes/462 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39698264
GET https://conductscience.org/api/papers/v1/39698264/references?page=2